Prelude Therapeutics (PRLD) Other financing activities (2019 - 2026)

Prelude Therapeutics has disclosed Other financing activities across 8 years of filings, most recently posting $294000.0 for Q1 2026.

• Other financing activities for Q1 2026 came in at $294000.0, down 92.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.4 million (up 16.32% YoY), and the FY2025 annual result was $11.9 million, up 10730.0% from the prior year.
• Other financing activities came in at $294000.0 for Q1 2026 at Prelude Therapeutics, down from $11.9 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $11.9 million in Q4 2025 to a low of $294000.0 in Q1 2026.
• The 5-year median for Other financing activities is $6.0 million (2022), against an average of $5.7 million.
• Across the five-year window, Other financing activities jumped 75.73% in 2022 and plunged 92.33% in 2026, its largest moves.
• Prelude Therapeutics' Other financing activities stood at $5.8 million in 2022, then climbed by 1.15% to $5.9 million in 2023, then advanced by 0.24% to $5.9 million in 2024, then soared by 101.03% to $11.9 million in 2025, then plunged by 97.53% to $294000.0 in 2026.
• The last three Other financing activities figures came in at $294000.0 (Q1 2026), $11.9 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.